Today's Date: February 3, 2023
Feinstein Institutes researcher discovers potential therapeutic target for lethal sepsis   •   American Marketing Association San Diego Launches New Sandie Awards and Opens Call for Entries   •   TWO PUBLIC ALLIES ALUMNI JOIN THE NATIONAL BOARD OF DIRECTORS   •   Conemaugh Miners Medical Center and Conemaugh Meyersdale Medical Center Achieve Designation as Lifepoint Health National Quality   •   Founder’s Day: Reflecting on a legacy of Black history at St. Jude Children’s Research Hospital   •   Boston Celtics and Sun Life close out 9th annual Fit to Win youth program with Celtics forward Justin Jackson at trampoline park   •   The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Veru Inc. (VERU)   •   US Fertility founding partner Shady Grove Fertility (SGF) announces Egg Freezing for Surgical Residents Program in celebration o   •   Government of Canada to support clean air and local economic growth by powering federal operations in Alberta and Saskatchewan w   •   Worldwide Shipments of Tablets and Chromebooks Declined Sharply in 2022, According to IDC Tracker   •   SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Honda Motor Co., Ltd. with Losses of $100,000 to Contact t   •   The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Affirm Holdings, Inc.   •   Introduction of Diagnostic and Supplemental Imaging Legislation Would Benefit Thousands of Marylanders   •   Scottsdale Tesla Drivers Club and PS Academy Arizona Work Together on Tesla Cybertruck Build   •   Hyundai and TEN Advertising Develop Their First Asian American Campaign "My Love, My Son-in-Law" for the Tucson SUV   •   Experiences of Black Women With Breast Cancer Highlight Need for Better Care, Improved Outcomes   •   The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NeoGenomics, Inc. (NE   •   General Dynamics Elects Richard Clarke to Board of Directors   •   INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Invivyd, Inc. f/k/   •   Joaquin Sabina in USA
Bookmark and Share

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. , December 07 /Businesswire/ - Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the company’s Board of Directors granted four employees nonqualified stock options to purchase 65,500 shares of its common stock with an exercise price of $7.07 per share, which is equal to the closing price of Kezar’s common stock on December 5, 2022, the grant date of the awards. The stock options were granted as an inducement award material to the individuals entering into employment with Kezar, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options will vest over a four-year period, with 25% of each option vesting on the first anniversary of the employee’s start date, and 1/48th of the total shares vesting monthly thereafter, subject to continued employment on each vesting date. The options are subject to the terms and conditions of Kezar’s 2022 Inducement Plan and the stock option agreement covering the grants.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing novel treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor has completed a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com.


STORY TAGS: Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, United States, North America, California, Stock Sale/Buyback,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News